Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614753 | 1.00 | KCNH2 (0.53) | KCNH2IGF1RALOX15TAAR1HDAC3 | |
| SCHEMBL8071211 | 1.00 | KCNH2 (0.53) | KCNH2IGF1RALOX15TAAR1HDAC3 | |
| SCHEMBL7464785 | 1.00 | KCNH2 (0.53) | KCNH2IGF1RALOX15TAAR1HDAC3 | |
| SCHEMBL5596095 | 1.00 | KCNH2 (0.53) | KCNH2IGF1RALOX15TAAR1HDAC3 | |
| SCHEMBL7562067 | 1.00 | KCNH2 (0.53) | KCNH2IGF1RALOX15TAAR1HDAC3 | |
| SCHEMBL11460578 | 1.00 | KCNH2 (0.53) | KCNH2IGF1RALOX15TAAR1HDAC3 | |
| SCHEMBL7562217 | 1.00 | KCNH2 (0.53) | KCNH2IGF1RALOX15TAAR1HDAC3 | |
| SCHEMBL1008937 | 0.98 | IGF1R (0.53) | KCNH2IGF1RALOX15TAAR1HDAC3 | |
| SCHEMBL81407 | 0.91 | TAAR1 (0.52) | KCNH2IGF1RALOX15TAAR1HDAC3 | |
| SCHEMBL8467011 | 0.89 | KCNH2 (0.45) | KCNH2IGF1RALOX15TAAR1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326713-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4525852-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023224893-A1 | INHIBITORS OF MSBA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20140171393-A1 | NOVEL AROMATIC THIO COMPOUNDS AS RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| CN-1105558-C | 2,2-dichloroalkane carboxylic acids, process for preparing the same, medicament containing the same and use for treating insulin resistance | ROCHE DIAGNOSTICS GMBH (DE) | 2003-04-16 | — | — | CN | disclosed |
| US-6545009-B1 | Imidazole, oxazole and thiazole derivatives for regulation of peroxisome proliferator-activated receptor function; improving insulin resistance, treating impaired glucose tolerance and obesity, enhancing insulin sensitivity, etc. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-04-08 | — | — | US | disclosed |
| EP-0637580-B1 | Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof | SUMITOMO CHEMICAL CO (JP) | 2002-08-14 | — | — | EP | disclosed |
| EP-0790824-B1 | 2,2-DICHLOROALKANE CARBOXYLIC ACIDS, PROCESS FOR PREPARING THE SAME, MEDICAMENT CONTAINING THE SAME, AND USE THEREOF FOR TREATING INSULIN RESISTANCE | ROCHE DIAGNOSTICS GMBH (DE) | 2002-02-06 | — | — | EP | disclosed |
| US-6071935-A | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors | PFIZER INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6063940-A | Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-05-16 | — | — | US | disclosed |
| EP-0637580-A1 | Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1995-02-08 | — | — | EP | disclosed |
| EP-0131302-B1 | IMIDAZOLIUM SALTS, INTERMEDIATES THERETO AND THEIR USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-29 | — | — | EP | disclosed |
| EP-0275024-B1 | CARBOXYLIC-ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1991-09-04 | — | — | EP | disclosed |
| US-4933367-A | Carboxylic acid derivatives, processes for the preparation thereof, the use thereof, and pharmaceutical compositions which contain these compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1990-06-12 | — | — | US | disclosed |
| US-4833161-A | ANTIDIABETIC AGENTS, ANTICHOLESTEROL AGENTS, ANTILIPEMIC AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-05-23 | — | — | US | disclosed |
| EP-0226636-B1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1989-02-08 | — | — | EP | disclosed |
| EP-0275024-A1 | Carboxylic-acid derivatives, processes for their preparation and medicaments containing these compounds | Roche Diagnostics GmbH (DE) | 1988-07-20 | — | — | EP | disclosed |
| EP-0226636-A1 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS. | BOEHRINGER MANNHEIM GMBH (DE) | 1987-07-01 | — | — | EP | disclosed |
| WO-1987000521-A2 | NEW CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURING PROCESS, USE AND MEDICINES CONTAINING THESE COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1987-01-29 | — | — | WO | disclosed |
| EP-0131302-A2 | Imidazolium salts, intermediates thereto and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 1985-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171393-A1 | NOVEL AROMATIC THIO COMPOUNDS AS RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | KCNH2 2282/4885IGF1R 653/4885ALOX15 2206/4885 |
| US-20250326713-A1 | INHIBITORS OF MsbA AS ANTIBIOTICS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MSRB3, ARSA, ABCG2 | KCNH2 1813/4885IGF1R 2156/4885ALOX15 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.